Drug Trial Radar · NCT01253642
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Last checked: Nov 20, 2026Latest source record: Oct 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Jul 12, 2010
Primary completion
Sep 15, 2016
Study completion Sep 15, 2017
Sponsor
- Lead sponsor
- OHSU Knight Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation
- First posted
- Dec 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel. Phenelzine sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Phenelzine sulfate may also help docetaxel work better by making tumor cells more sensitive to the drug. Giving phenelzine sulfate together with docetaxel may kill more tumor cells.
Conditions
- Hormone-Resistant Prostate Cancer
- Metastatic Prostatic Adenocarcinoma
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
Interventions
Biopsy of ProstateProcedure
Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
DocetaxelDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
Phenelzine SulfateDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Who Experience a PSA (Prostate-Specific Antigen) Decline of at Least 30%Time frame: Within 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
OHSU Knight Cancer Institute
Portland, Oregon
Fred Hutchinson Cancer Research Center
Seattle, Washington
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.